

**Role of overexpression mTORC1 in diabetes mellitus type 2: activation PI3K/Akt pathway**

Martín Pérez-Vázquez <sup>1</sup>, Psarova O. V <sup>1,2</sup>, Palero S <sup>\*1</sup>



**Abstract**

The objective of this study is to investigate the role of excessive activation PI3K/Akt/mTORC1 in diabetes mellitus type 2. It's known that the PI3K/Akt/mTORC1 pathway is involved in the pathogenesis of cancer. The study design was carried out per the guidelines of the Helsinki Declaration that included normal patients as control ( $n = 15$ ), the second group included patients with diabetes mellitus type 2 ( $n = 22$ ) while the third group included patients with malignancy-positive mTORC1 ( $n = 22$ ). 81 women were examined and enrolled in this study with age from 40- to 75 years old. Diabetes mellitus type 2 compensation was assessed by determining the level of HbA1c by the method of ion-exchange chromatography, using the BIO-RAD D-10 analyzer, PRAS40 was determined in units depending on the amount of protein in the blood cell lysates.

**Keywords:** Diabetes mellitus type 2; mTORC1; PI3K/Akt


\*Corresponding author email: Palero.s23@ti.vpinu

<sup>1</sup> Servicio de Aparato Digestivo, Spain.

<sup>2</sup> Department of Pathology of Sumy State University, Ukraine

Received September 10, 2022; revised November 14, 2022; accepted December 03, 2022; published January 04, 2023

Copyright © Palero S et al., 2023. This is article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0) (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Introduction**

Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, nerves, heart, and blood vessels [1, 2].

Signal pathway PI3K/Akt/mTOR is one of these regulatory systems, its dysregulation leads to severe diseases such as cancer and type 2 diabetes (T2D) [3]. Insulin and insulin-like growth factor (IGF-1) are the main stimulators of this pathway in patients with DM [4]. Hyperinsulinemia promotes the IGF bioavailability due to the decrease in the synthesis of IGF-binding proteins 1, 2 (IGFBP1, 2) in the liver, as well as through the indirect effects on growth hormone (GH) secretion [5]. mTOR (mammalian target of rapamycin) includes two complexes: mTORC1 and mTORC2. Raptor (regulatory-associated protein of mTOR) and PRAS40 (proline-rich Akt substrate 40kDa) are specific for mTORC1.



mTORC1 is a highly conserved serine/threonine protein kinase, which controls the cell growth and homeostasis, including protein synthesis, lipogenesis, glucose metabolism, autophagy, biogenesis of ribosomes and lysosomes, proliferation and survival in response to environmental signals such as amino acid levels, glucose, energy, oxygen, and growth factors [6]. Raptor is a scaffolding protein that mobilizes substrates for the mTOR kinase, interacting with their motifs (TOR signaling) [6].

PRAS40 is Akt1-1 substrate (AKT1S1) and component of the mTORC1/p70S6K signaling pathway [5]. PRAS40 is both a substrate and a negative regulator of mTORC1 and is phosphorylated by Akt, Pim-1 (T246) and mTORC1 (S183/S212/S221). Phosphorylation causes binding of PRAS40 to the protein 14-3-3, to the dissociation of PRAS40 and raptor and, respectively, the activation of mTORC1 [8]. The increased level of PRAS40 phosphorylation was detected by several types of tumors [9]. Activated mTORC1 phosphorylates and changes functional activity of S6K-protein kinase (p70S6K1), which is responsible for protein synthesis in ribosomes and regulates growth, proliferation, apoptosis, cell's survival, as well as metastasis and invasion of cancer cells [10].

Phosphorylation of p70S6K1 through activated mTOR enhances of insulin resistance [11]. The composition of leukocytes includes several types of cells that play an essential role in the development of pathological conditions: cancer, diabetes and its complications [4]. Taking into account the effects of pathogenetic factors of T2D on the activity of the signal path, the determination of content of phosphorylated kinase PRAS40, p70S6K may have an additional value for determining oncological risk in patients with T2D [12]. Our aim was to study the Role of overexpression mTORC1 in diabetes mellitus type 2: activation PI3K/Akt pathway.

## Materials and methods

The clinical trial was carried out in accordance with the guidelines of the Helsinki Declaration (1975) and its revised version of 1983. All patients signed an informed consent for further diagnostic and research work. During the study 81 patients were examined. All examined patients belonged to the Caucasian race, age was in range from 46 to 72. The bases for the study were: PR Carpathian Oncology Center and Regional Clinical Hospital in Ivano-Frankivsk. All the patients involved were women in order to avoid the inaccuracies during calculations and as two of the oncological diseases described in this study have gender specifics.

Patients were divided into groups: I – healthy (control group) (n = 15), II – patients with T2D (n = 22), III – patients with cancer (n = 22). Patients were grouped accordingly to age and BMI. All patients with T2D used different kinds of therapy, including antidiabetic pills, insulin or their combinations. In the investigation were involved women with endometrial, breast and colorectal cancer. Blood collection was carried out before special anti-tumor therapy: chemotherapy, hormonal therapy or radiotherapy. Immediately after collection blood was centrifuged at RT in the 15 ml conical Falcon TM tubes using Histopaque 1077 (Sigma, USA) as a substrate, collected lymphocytes were washed in PBS and frozen at -80°C until further use.

For determinations of phospho-PRAS40 (phosphoT246) and phospho-p70S6K1 (phospho-T389) amount ELISA kits KHO0421 and 85-86053 respectively (both from Invitrogen, USA) were used. The studies were carried out in triplets. The cells were lysed in the extraction buffer with inhibitors of proteases and phosphatases from the kit. The protein concentration in the lysate was determined using Novagen (USA) BCA protein assay kit. The measurements were carried out on a microplate reader (Bio-tek Instruments, USA) at a wavelength of 450 nm. The OD values of samples obtained are located on the calibration curve satisfactorily coinciding with a theoretical curve that indicates no scattering of the data. DM compensation was assessed by determining the level of HbA1c by the method of ion-exchange chromatography, using the BIO-RAD D-10 analyzer, the BIO-RAD (USA) reagents. PRAS40 was determined in units, according to the study guide; the level of p70S6K1 was determined in conventional units, depending on the amount of protein in the blood cell lysates.

### Statistical analysis

The data are presented in tables as  $x \pm SD$  ( $x \pm$  standard deviation). Differences between the values in the control and experimental groups were determined using the student's t-test. The results are presented with statistical significance or *P* value ( $*p < 0.05$ ).

### Results

The results confirm the frequent clinical cases of cancer in people aged over 55 years on the background of obesity. HbA1c levels in II and IV groups of patients were higher than 7.5% (Table 1).

**Table 1.**

Characteristics of patients in this study.

Indexes	I group (n = 15)	II group (n = 22)	III group (n = 22)	IV group (n = 22)
Age (years)	55.0 ± 22.5	60.90 ± 2.8	58.8 ± 2.3	60.0 ± 1.42
BMI (kg/m <sup>2</sup> )	31.21 ± 1.09	30.09 ± 1.04	31.17 ± 0.22	31.8 ± 1.12
HbA1c (%)	Negative	7.43 ± 1.24	Negative	7.13 ± 0.95


\* The difference from the control group is significant,  $P < 0.05$

The amount of phosphorylated PRAS40 significantly increases in leukocytes of patients of group II with T2D and of group III with cancer but decreases in patients with combination of diabetes and cancer compared to control group ( $P < 0.05$ ) (Figure 1).

Level of phospho-PRAS40 in women of group IV was significantly decreased in comparison to patients from other experimental groups ( $P < 0.05$ ) (Figure 1).

The number of phospho-PRAS40-positive samples in patients with T2D was 83.3%, and in patients with cancer – 66.7%. According to the results of study, significant increase in the p70S6K1 phosphorylation was detected in groups of patients with T2D and with cancer compared to control group ( $P < 0.05$ ).

Level of phospho-p70S6K1 in women of group IV was significantly decreased compared to patients from the other experimental groups ( $P < 0.05$ ), but not significantly, compared to control group. Significant difference in the activity of kinases PRAS40 and p70S6K in the PBMC between patients with different types of cancer within groups III and IV was not observed ( $P > 0.05$ ).



**Figure 1.**

Content of phospho-p70S6K1 in patients with T2D and cancer,  $P < 0.05$ .

## Discussion

Increased level of phosphoPRAS40 in most of the patients of group II with T2D and patients of group III with cancer confirms the mTORC1 activation by these diseases [13]. It is known that tissues of patients with T2D are characterized by enhanced activity of mTORC1 and its substrate p70S6K, resulting in phosphorylation of IRS-1 (S307 and other residues), impairment of insulin signaling and, consequently, insulin resistance [3].

Increased level of phosphorylated PRAS40 in patients with T2D, besides possible changes due to disease, is probably determined by the ratio of complex effects of metformin and insulin, which were taken by patients [14]. Metformin lowers mTORC1 activity but on the other hand improves insulin signaling. Insulin activates mTORC1 via the signaling cascade of PI3K/Akt/mTORC1 [6] and inhibits the activation of AMPK by metformin [9], which in its turn inhibits mTORC1 [15].

The final result of the interaction of these drugs and the signaling mechanisms that they induced, obviously, is the enhanced phosphorylation of the mTORC1 inhibitor – PRAS40 [16].

Although the implementation of the insulin signal in the cell occurs through phosphorylation and sequestration of PRAS40, silencing of the AKT1S1 gene promotes the degradation of the IRS1 in skeletal muscle via proteasome activation, which leads to an impairment of the IRS-1/Akt signaling pathway that regulates glucose transport into the cells [17]. Excessive expression of PRAS40 inhibits proteasome activation and increases the stability of IRS-1, which leads to an increase of insulin sensitivity [18].

Hyperexpression of PRAS40 improved signaling of insulin in the heart and liver of mice on a high-fat diet [19]. Also, AKT1S1 knockout reduces the phosphorylation of mTORC1 substrates in certain cell types, indicating the importance of PRAS40 for PI3K/Akt/mTORC1 signaling through unclear mechanisms [6]. Knockout of PRAS40 in primary human skeletal muscle cells reduced insulin-mediated phosphorylation of Akt by 50%, as well as that of Akt substrates GSK-3 (Glycogen synthase kinase-3) by 40% and TSC2 (Tuberous Sclerosis complex 2) by 32% [20].

The latter fact testifies to the negative regulation by PRAS40 of its own phosphorylation. In addition, the activity of mTORC1 is positively regulated via PRAS40 phosphorylation by mTORC1, which leads to amplification of the signal [21]. Consequently, the role of PRAS40 is not limited to negative regulation of the mTORC1 activity. Apparently, it performs more complex functions in insulin signaling. Hyperactivation of mTORC1 is often observed by sporadic cancers.

Several types of tumors demonstrated an increase in the level of PRAS40 phosphorylation [9], which is associated with enhanced activity of kinases such as Akt, Pim-1 and mTORC1. The intensification of the translation caused by aberrant activation of mTORC1 leads to an increase in the cell size and proliferation, two common cancer features, and the search for mTORC1 inhibitors is considered a promising approach for the cancer treatment [6]. From this perspective, the increased activity of mTORC1 in leukocytes is of interest because it may serve as an additional diagnostic marker of the disease. Some of the PRAS40 functions, such as regulation of the nucleolar stress response, proteasome activity and cell survival, suggest that PRAS40 may be involved in the progression of malignant tumors. The phosphorylated PRAS40- T246 may also be a biomarker for predicting the susceptibility to inhibitors of Akt in cancer patients [22].

It was assumed that in the leukocytes of the patients of group with both cancer and diabetes, an additive effect on phosphorylation of PRAS40 would be observed. Therefore, somewhat unexpected was a decrease in the amount of phospho-PRAS40 below the control level (Figure 1). Consequently, in patients of the latter group, the activity of mTORC1 and p70S6K1 in leukocytes may be depressed, in comparison with control and, especially, with groups of patients with diabetes and cancer.

The decrease in PRAS40 phosphorylation in leukocytes in a group of patients with cancer and diabetes may be explained by competition for common signaling mechanisms [23]. Also, antagonistic interaction between the two main cascades controlling proliferative processes –

PI3K/Akt and MAPK – is not excluded. It has been shown that the MAPK/ERK signaling pathway can also activate mTORC1, both by phosphorylation of TSC2 and PRAS40 [6].

It is also known that an excess of insulin by diabetes can stimulate proliferative processes and malignant transformation through the Ras/MAPK/ERK1/2 cascade [23]. Thus, PRAS40 phosphorylation in leukocytes largely determines activity of mTORC1 and p70S6K1. These data are confirmed by the results of the study of p70S6K1 phosphorylation (T389) and activation. The pattern of the PRAS40 phosphorylation in general coincides with the phosphorylation of the mTORC1 substrate – downstream protein kinase p70S6K1. The composition of leukocytes includes monocytes/macrophages (up to 11% of the total amount of leukocytes) and lymphocytes (up to 40%) involved in the processes of cellular and humoral immunity.

Macrophages and lymphocytes are involved in the pathogenesis of diabetes, diabetic atherosclerosis, formation of insulin resistance as well as immune response to cancer and tumor maintenance. The signaling pathway PI3K/Akt/mTORC1 activity in leukocytes plays an important role in these processes [24].

It has been shown that this cascade is responsible for the differentiation of immune cells involved in tumor recognition, clearance and mechanisms of cancer escape from immunological surveillance [25]. In leukocytes mTOR regulates the IL-12 synthesis and secretion, which plays an important role in the activities of natural killer cells and T-lymphocytes [8]. The activation of mTOR/S6K signaling upon NKG2D/DAP10 receptor complex stimulation promotes cancer progression through an enhanced energetic metabolism [26]. Targeting mTORC1 is a promising strategy in cancer therapy [27].

Thus, the present study showed that phosphorylation of PRAS40 is generally consistent with the activation of mTORC1, as measured by phosphorylation of p70S6K1. The increasing of the levels of phospho-PRAS40 and phospho-p70S6K1 in patients with cancer and in patients with T2D is a sign of mTORC1 activation for both types of diseases. The decrease of phospho-PRAS40 in patients with a combination of T2D and cancer may be explained by the involvement of other intracellular regulatory systems of oncogenesis and metabolism that inhibit mTOR signaling

## Conclusion

The increased amount of phosphorylated PRAS40 and p70S6K1 proves the activation of the studied signaling pathway by DM2. Its decrease in case of presence of both diabetes and cancer can be explained by the possible competing effects of the proteins that affect upstream regulators of these kinases or them directly. The exact explanation of the occurrence of this peculiarity requires the further study of the changes of intracellular processes by these diseases.

## Competing interests

The authors declare no conflict of interest.

### **Ethics Statement**

This study has been approved by the Ethical Review Committee of the Servicio de Aparato Digestivo. The publication of any potentially identifiable images or data contained in the article requires personal written informed consent. The research team will provide consultations for all subjects and their families to answer any research questions. Before signing the informed consent form, after the patients and their families fully understand the research process, our team members will organize the patients to sign the informed consent form or withdraw from the research. All subjects or their guardians will sign informed consent. Authors tend to submit research results to peer-reviewed journals or academic conferences for publication.

### **Authors' contributions**

All authors shared in the conception and design and interpretation of data, drafting of the manuscript and critical revision of the case study for intellectual content and final approval of the version to be published. All authors read and approved the final manuscript.

### **Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

<http://creativecommons.org/licenses/by-nc/4.0/>.

### **References**

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; 20:1183–1197.
2. Pradhan AD, Rifai N, Buring JE, Ridker PM. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. *Am J Med* 2007; 120:720–727.
3. Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y, Endo G, Kambe H. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. *Diabetes Care* 2009; 32:644–646.
4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002; 346:393–403.
5. Kasuga M. Insulin resistance and pancreatic  $\beta$ -cell failure. *J Clin Invest* 2006; 116:1756–1760.
6. Tuttle RL, Gill NS, Pugh W, et al. Regulation of pancreatic  $\beta$ -cell growth and survival by the serine/threonine protein kinase Akt1/PKB $\alpha$ . *Nat Med* 2001; 7:1133–1137.



7. Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA. Islet  $\beta$ -cell expression of constitutively active Akt1/PKB $\alpha$  induces striking hypertrophy, hyperplasia, and hyperinsulinemia. *J Clin Invest* 2001; 108:1631– 1638.
8. Stiles BL, Kuralwalla-Martinez C, Guo W, et al. Selective deletion of Pten in pancreatic  $\beta$ -cells leads to increased islet mass and resistance to STZ-induced diabetes. *Mol Cell Biol* 2006; 26:2772– 2781.
9. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell* 2006; 124:471– 484.
10. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. *Curr Opin Cell Biol* 2005; 17:596– 603.
11. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. *Cell* 2002; 110:177– 189.
12. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a component of the insulin/TOR signaling network. *Nat Cell Biol* 2003; 5:566– 571.
13. Garami A, Zwartkruis FJT, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. *Mol Cell* 2003; 11:1457– 1466.
14. Yeung SC. PIM1 (pim-1 oncogene). *Atlas Genet Cytogenet Oncol Haematol* 2013; 17(10): 704-8.
15. Long X, Ortiz-Vega S, Lin Y, Avruch J: Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. *J Biol Chem* 2005; 280: 23433– 23436.
16. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in  $\beta$ -cells. *J Biol Chem* 2005; 280:2282– 2293.
17. Wang H, Zhang Q, Wen Q, et al. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. *Cell Signal* 2012; 24(1): 17-24.
18. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. *Curr Diab Rep.* 2006; 6:479–83.
19. De Oliveira CE, Oda JM, Losi Guembarovski R, et al. CC chemokine receptor 5: the interface of host immunity and cancer. *Dis Markers.* 2014; 2014: 126954.
20. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. [Trial watch: Prognostic and predictive value of the immune infiltrate in cancer]. *Oncoimmunology.* 2012; 1(8):1323-1343.
21. Dituri F, Mazzocca A, Giannelli G, Antonaci S. PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors]. *Clin Dev Immunol.* 2011; 2011:947858.
22. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. *Cell.* 2003;115:577–90.
23. Lu Q, Zuo WZ, Ji XJ, et al. Ethanolic Ginkgo biloba leaf extract prevents renal fibrosis through Akt/mTOR signaling in diabetic nephropathy. *Phytomedicine.* 2015; 22:1071–8.
24. Yang Y, Han Y, Zuo Y, et al. Hedgehog signaling pathway for advanced ovarian cancer: cross-talk mTOR/AKT kinase. *American Journal of BioMedicine* 2016; 4(11):505-512.
25. Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. *Cancer Biol Ther.* 2011; 12(12):1032-1049.





26. Yoon MS. [The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling]. *Nutrients*. 2017; 9(11):1176.
27. Zhang Z, Li BY, Li XL, et al. Proteomic analysis of kidney and protective effects of grape seed procyanidin B2 in db/db mice indicate MFG-E8 as a key molecule in the development of diabetic nephropathy. *Biochim Biophys Acta*. 2013; 1832:805–16.



**American Journal of BioMedicine**

Journal Abbreviation: AJBM  
ISSN: 2333-5106 (Online)  
DOI: 10.18081/issn.2333-5106  
Publisher: BM-Publisher  
Email: editor@ajbm.net

